MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis.
about
Biological effects and safety in magnetic resonance imaging: a reviewCardiovascular magnetic resonance: Diagnostic utility and specific considerations in the pediatric population.Indications for cardiovascular magnetic resonance in children with congenital and acquired heart disease: an expert consensus paper of the Imaging Working Group of the AEPC and the Cardiovascular Magnetic Resonance Section of the EACVINephrogenic systemic fibrosis: a concise review for cardiologists.Reliability of magnetic resonance elastography using multislice two-dimensional spin-echo echo-planar imaging (SE-EPI) and three-dimensional inversion reconstruction for assessing renal stiffness.Safety in magnetic resonance units: an update.Recommendations for cardiovascular magnetic resonance in adults with congenital heart disease from the respective working groups of the European Society of Cardiology.High relaxivity Gd(III)-DNA gold nanostars: investigation of shape effects on proton relaxation.Multimodality imaging probes: design and challenges.Pulmonary Nodule Detection in Patients with a Primary Malignancy Using Hybrid PET/MRI: Is There Value in Adding Contrast-Enhanced MR Imaging?Evaluation of a handheld creatinine measurement device for real-time determination of serum creatinine in radiology departments.Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases.Perianal Fistula With and Without Abscess: Assessment of Fistula Activity Using Diffusion-Weighted Magnetic Resonance Imaging.Magnetic resonance imaging of cardiovascular fibrosis and inflammation: from clinical practice to animal studies and backAngiotensin-converting enzyme inhibitor-enhanced MR renography: repeated measures of GFR and RPF in hypertensive patientsGd(III)-Dithiolane Gold Nanoparticles for T1-Weighted Magnetic Resonance Imaging of the Pancreas.Imaging of musculoskeletal soft tissue infections.Gd(III)-Gold Nanoconjugates Provide Remarkable Cell Labeling for High Field Magnetic Resonance Imaging.Extremity magnetic resonance imaging in rheumatoid arthritis: Updated literature review.Is administration of gadolinium-based contrast media to pregnant women and small children justified?MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials.Contrast-enhanced MRI of murine myocardial infarction - part I.The current status of positron emission mammography in breast cancer diagnosis.Diffusion-weighted MRI of the abdomen: current value in clinical routine.Diagnosis of intracranial atherosclerosis.Diffusion-weighted MRI of metastatic liver lesions: is there a difference between hypervascular and hypovascular metastases?Gadolinium and nephrogenic systemic fibrosis: an update.Magnetic resonance imaging of the gut: a primer for the luminal gastroenterologist.Management of incidental renal masses: Time to consider contrast-enhanced ultrasonography.Repeatability of Non-Contrast-Enhanced Lower-Extremity Angiography Using the Flow-Spoiled Fresh Blood Imaging.Generic gadolinium-based contrast agents: the future?Cost-effectiveness analysis of a non-contrast screening MRI protocol for vestibular schwannoma in patients with asymmetric sensorineural hearing loss.Time-resolved MR angiography of renal artery stenosis in a swine model at 3 Tesla using gadobutrol with digital subtraction angiography correlation.The gadolinium-based contrast agent Omniscan® promotes in vitro fibroblast survival through in situ precipitation.Lanthanides inhibit adipogenesis with promotion of cell proliferation in 3T3-L1 preadipocytes.Skull base CT: normative values for size and symmetry of the facial nerve canal, foramen ovale, pterygoid canal, and foramen rotundum.PET-guided breast biopsy.Synthesis and In Vitro Characterization of Fe3+-Doped Layered Double Hydroxide Nanorings as a Potential Imageable Drug Delivery System.Diagnostic performance of intravoxel incoherent motion diffusion-weighted imaging and dynamic contrast-enhanced MRI for assessment of anal fistula activity.Candidate biomarkers of extravascular extracellular space: a direct comparison of apparent diffusion coefficient and dynamic contrast-enhanced MR imaging--derived measurement of the volume of the extravascular extracellular space in glioblastoma mul
P2860
Q22064516-EB894853-D24F-4DDA-A292-EC534914A76BQ26767019-3B43CB30-A312-4BC0-A40D-28F1F1FAD094Q26829408-F27AC482-13BC-4946-8493-04BE744504EFQ28972564-CE9C11A9-3D36-41FC-B652-AC67CDF2A589Q30375325-8D96BE3B-BF30-46F2-AA2E-C04809807C06Q30480343-8553CA86-D8F2-45A4-A096-B208B95EA384Q30482226-57032511-C633-4946-A2DA-F16254E3A5DFQ30901328-2590D104-65DC-41DE-86EF-90E0BB96E865Q33884695-5F94CC16-68EF-42DE-A5BF-AC1D865674E4Q35660961-0A9B5601-702E-44A2-BDB3-149896B4340CQ36166567-EE2D695F-72F8-4BB4-B060-1D80DEE760B2Q36324674-2F0BA1CA-3F99-4245-BD3F-504461F5C146Q36405420-4ACCF5D7-46C9-446F-AB6F-7389A1D6E2FAQ37154775-45ABDEA7-85F4-4DF7-B782-9A6237AA6EBAQ37162342-4F433ABE-DF87-428C-82AB-FC7DF5024A05Q37302810-67129619-A3C4-4545-B6B7-E509EC43C1CCQ37588532-2B6EE428-8750-464C-B395-0CBC6611A21FQ37592465-FECAFBEC-5718-489D-95C0-B7F450D68611Q37817066-CD544698-62D0-4CDE-A7F8-C6767E88F70BQ37934729-F06DA0BC-4C57-4048-BFC9-4E1186E7AE70Q37964985-8F7C56FC-EB9C-42D0-BCE1-A8F0C1F94BEBQ37981643-BB2E092F-1CB7-4EC3-A341-C4B1223297C1Q38067336-D3FAA2CB-2D7B-433A-993A-286EABADAB0FQ38068826-EF224D2B-17AD-40AA-83CE-9178D16B5B9CQ38089084-932C4147-13CC-42EE-9ED8-00F2B3BC830BQ38132368-64E03F7E-C683-4B00-84F0-D37D698F32A4Q38154533-E2CF5ED7-277B-4785-B8C6-6AB3E9088A16Q38176213-ADA4020C-DF85-4547-8B3E-4E1D84736609Q38567389-73DF3FAA-CC7D-4978-9958-7AF80EFE761CQ38634717-6A3FFD94-9D1F-4DCB-A05F-4F6A9B09BBC1Q38660417-BC4E137C-360D-4E4C-A01C-A8A18607345EQ38721655-5E38FD38-E1C6-46D5-B0E1-BCF45525A694Q40037831-20C5986F-B9FE-43E6-881D-0DF9C0C7AC64Q41082208-9104D592-09FA-4211-AD4F-C548D5DE4683Q42820726-F50575AE-2607-4B98-AAF3-B0BE4C06C745Q45209609-B01EB8B7-6989-45AB-9725-37CC39CFCB40Q46018033-0264B43C-2F95-4732-B775-D95B6436FD5DQ47100910-431166B6-9CFC-4D91-BB09-2D6927C2825BQ48165372-23F81ADF-DEB6-48F5-BB08-318C16C130BEQ48426682-9B8A97DE-202C-4C68-934A-665F7372356C
P2860
MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis.
@en
MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis.
@nl
type
label
MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis.
@en
MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis.
@nl
prefLabel
MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis.
@en
MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis.
@nl
P356
P1476
MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis.
@en
P2093
Alberto Spinazzi
Frank G Shellock
P304
P356
10.2214/AJR.08.1038.1
P407
P577
2008-10-01T00:00:00Z